Sven Kili

20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT.

University Health Network operates as a healthcare and medical research organization that provides patient care, education, and research services. Its programs include arthritis program, joint department of medical imaging, Krembil neuroscience center, laboratory medicine program, medical and community care, multi-organ transplant, Peter Munk cardiac center, Princess Margaret cancer, surgery and critical care program, and Toronto rehab. The company was founded in 1986 and is headquartered in Toronto, Canada.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Lonza Walkersville, Inc. develops, manufactures and provides testing services for cell-based therapeutics. Its services include life-science customers, research organizations, pharmaceutical, biopharmaceutical, biotechnology and generic drug companies. The company was founded was founded on May 9, 1991 and is headquartered in Walkersville, MD.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Rimon Therapeutics Ltd. develops and markets pharmaceutical products. The company was founded by Michael May and is headquartered in Mississauga, Canada.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

Nezu Asia Capital Management Ltd. (Nezu HK) is the alternative investment management subsidiary of Nezu Group S.A.R.L., itself owned by Nezu Group LP in the US. Headquartered in Hong Kong, Nezu HK was founded in 2004 and they provide discretionary investment advisory services to separately managed accounts and a private investment fund, which is open only to certain financially sophisticated and high-net worth individuals and entities.

AssureImmune LLC provides stem cell banking and storage services. The firm is a science-based cell preservation industry specializes in the collection, testing and banking of cord blood and adult stem cells. It also specializes in immunology, cellular transplantation. The company was founded by Claudia Zylberberg and Javier Zylberberg and is headquartered in Miami, FL.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden.

AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden.

Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Nezu Asia Capital Management (Singapore) Pte Ltd. (Nezu Asia SG) is an independent hedge fund manager headquartered in Singapore. Nezu Asia SG manages long/short equity portfolios.

Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden.

Nezu Master Strategy Feeder Ltd. Operates as a private equity fund. The company is headquartered in Grand Cayman, Cayman Islands.

Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.

Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden.

The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022.

The Centre for the Commercialization of Antibodies & Biologics is a Canadian company that manufactures pharmaceutical products.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018.

Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti.

Ryne Biotechnology, Inc. is an American US-based biotechnology company that focuses on developing next-generation approaches to cure neurological disorders. The company utilizes induced pluripotent stem cell (iPSC) technology to advance its off-the-shelf neuron replacement therapeutics. Ryne Bio is dedicated to advancing a pipeline targeting neurological diseases by focusing on an iPSC technology platform and forging partnerships with leaders in surgical delivery and clinical development.